Literature DB >> 28463078

Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases.

Jiejing Qian1, Jie Jin1,2, Hong Luo3, Chunji Jin1, Lei Wang1, Wenbin Qian1, Haitao Meng1.   

Abstract

OBJECTIVE: This study aims to explore the clinical features of multiple myeloma (MM) and the influence of various prognostic factors on survival.
METHODS: A retrospective analysis, consisting of clinical characteristics analysis and laboratory examinations, was performed on 787 MM patients. Clinical and laboratory parameters were analyzed by multivariate process and compared across different groups.
RESULTS: Of the 787 patients enrolled (median age, 61 years old, range 29-89 years old), 491 (62.4%) were male. Two most common complaints were bone pain (51.2%) and fatigue (48.0%). Anemia (hemoglobin (Hb) ≤100 g/L in female, Hb ≤110 g/L in male) was present initially in 69.4% patients. IgG was the most common type (46.6%). 52.2% of the patients were diagnosed on stage IIIA according to Durie-Salmon (D-S) system, 44.6% are on stage III according to International Staging System (ISS). Multivariate analysis suggested that age, serum calcium, LDH, percentage of abnormal plasma cells in bone marrow were all independent prognostic factors for OS.
CONCLUSION: The MM patients in China are relatively younger, have higher rate on stage III according to D-S system. Older age, high serum calcium, high LDH, high percentage of abnormal plasma cells in bone marrow were highly related to poor prognosis.

Entities:  

Keywords:  Multiple myeloma; clinical features; prognostic factors

Mesh:

Substances:

Year:  2017        PMID: 28463078     DOI: 10.1080/10245332.2017.1309493

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  6 in total

1.  Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.

Authors:  Abdullah S Al Saleh; Harsh V Parmar; Alissa Visram; Eli Muchtar; Francis K Buadi; Ronald S Go; Angela Dispenzieri; Prashant Kapoor; Rahma Warsame; Martha Q Lacy; David Dingli; Nelson Leung; Wilson I Gonsalves; Taxiarchis V Kourelis; Morie A Gertz; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-04-07

2.  Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation.

Authors:  Daria Ripani; Carmelo Caldarella; Tommaso Za; Daniele Antonio Pizzuto; Elena Rossi; Valerio De Stefano; Alessandro Giordano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-27       Impact factor: 9.236

3.  Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients.

Authors:  Liang Chen; Ke Yi; Hongyan Lan; Yajun Zhang; Simin Jin; Xiaoyu Mou; Hongming Xian; Weijun Fu; Rong Li
Journal:  Ann Transl Med       Date:  2022-06

4.  Complement 4 Aids in the Prediction of Newly Diagnosed Multiple Myeloma Outcome in Patients.

Authors:  Lihua Zhang; Xiaosui Ling; Fan Li; Tonghua Yang; Keqian Shi; Shixiang Zhao; Liqun Yu; Zengzheng Li; Haiping He
Journal:  Clin Med Insights Oncol       Date:  2022-02-28

5.  Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report.

Authors:  Tao Wu; Jinmao Zhou; Cunbang Wang; Binbin Wang; Shuting Zhang; Hai Bai
Journal:  Oncol Lett       Date:  2017-10-09       Impact factor: 2.967

Review 6.  Immunological Prognostic Factors in Multiple Myeloma.

Authors:  Dominika Bębnowska; Rafał Hrynkiewicz; Ewelina Grywalska; Marcin Pasiarski; Barbara Sosnowska-Pasiarska; Iwona Smarz-Widelska; Stanisław Góźdź; Jacek Roliński; Paulina Niedźwiedzka-Rystwej
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.